ARTICLES IN THREE SENTENCES
Germline GATA2 variant disrupting endothelial eNOS function and angiogenesis can be restored by c-Jun/AP-1 upregulation
Germline GATA2 gene variants have been associated with several inherited and acquired hematologic disorders, and thrombosis has been reported in 25% of patients. Authors demonstrated that GATA2 deficiency is associated with defective expression of eNOS by platelets and endothelial cells with impaired NO production, suggesting that this may represent an important thrombogenic mechanism. They also identified a therapeutic option, through atorvastatin, able to restore eNOS expression and angiogenesis in GATA2 deficiency in vitro.
SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
This study includes all consecutive WHO-defined MDS/MPN patients of Mayo Clinic from 1994 to 2020.Next-generation sequencing information at diagnosis was available for 444 (57%) patients. Authors combined all SF3B1-mutant MDS/MPN patients into one category (n=78) and compared them to their wild-type counterparts (n=446). Leukemia-free survival and overall survival in MDS/MPN patients with SF3B1 mutations were significantly better compared to SF31B wild-type MDS/MPN patients.
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study
Data regarding efficacy and toxicity of CAR-T cell therapy in the elderly, geriatric population are insufficient. This study explored the characteristics and outcome of 47 consecutive patients, 70 years or older, referred for CAR-T. The outcomes of CAR-T cell therapy are comparable between elderly, geriatric and younger patients, indicating that age as per se should not preclude CAR-T cell administration.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
In this prospective pilot study, authors evaluated a rituximab/prednisone prephase treatment strategy in 33 older, vulnerable patients with newly diagnosed DLBCL. This prephase therapy was feasible with acceptable toxicity profiles and excellent long-term survival. Prephase therapy with rituximab/prednisone should be considered for all older, vulnerable DLBCL patients prior to curative intent, anthracycline-based chemoimmunotherapy.
TAKE ADVANTAGE FROM HAEMATOLOGICA